Stan Bernard

Stan Bernard outlines the seven ways for pharmas to ensure successful execution of action steps following brand ‘war games’.

The seven ways for pharmas to ensure successful execution of action steps following brand "war games."

Biopharma companies are increasingly leveraging product portfolios to own and dominate strategically important therapeutic areas.

For years, many companies have competed to demonstrate that their products could achieve the holy grail in type 2 diabetes (T2D): cardiovascular (CV) risk reduction. According to the American Diabetes Association, pharma companies to date have spent over $2 billion and tested 138,000 patients in company-sponsored CV-risk reduction T2D trials, including the recent large-scale TECOS, SAVOR, EXAMINE, and ELIXA studies. 

As more new products vie for payer and prescriber attention, the stakes around launch success are higher than ever. Here are key traps to avoid in getting things right-when it really counts.

Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training.